Most of the palmitoylethanolamide (PEA) research covered on this site is about pain: neuropathic pain, fibromyalgia, low back pain, migraine. There is a separate and surprisingly old line of PEA research that has nothing to do with pain at all. Since 2011, ophthalmology groups in Italy have been running clinical trials on whether oral PEA lowers intraocular pressure (IOP) in people with glaucoma and ocular hypertension.
This is one of the few PEA applications where the human trials are randomized, the outcome measured is an objective number rather than a symptom questionnaire, and the effect size has been replicated across more than one research group. It is also one where the evidence is much smaller in total than the headlines suggest, and where nobody is claiming PEA replaces glaucoma medication. Here is what the actual trials found.
Key Takeaways
- A 2011 randomized, double-blind, crossover trial in 42 patients on timolol found oral PEA 300 mg twice daily lowered IOP by 3.5 mmHg (about 16%) at two months, versus 0.3 mmHg on placebo [1].
- A 2014 six-month study in normal-tension glaucoma found PEA lowered IOP from 14.4 to 11.1 mmHg and improved visual field indices, while the untreated comparison group did not change [2].
- A 2020 crossover trial using pattern electroretinogram found PEA 600 mg daily improved a direct electrophysiological measure of retinal ganglion cell function, alongside a 1.6 mmHg IOP drop [3].
- A 2025 systematic review and meta-analysis found only six eligible studies covering 199 patients in total, three of which could be pooled [4]. This is a small literature.
- Every one of these trials used PEA on top of existing glaucoma treatment, not instead of it. Nothing here supports stopping prescribed eye drops.
Why an Anti-Inflammatory Fatty Acid Would Affect Eye Pressure at All
Glaucoma is usually described as a pressure problem, but it is more accurately a neurodegenerative one: retinal ganglion cells die over time, and elevated IOP is the main modifiable risk factor driving that loss. That framing matters, because it means a compound could plausibly help in two separate ways, by lowering the pressure and by protecting the nerve cells directly.
PEA has a mechanistic case for both. Its established anti-inflammatory action runs through PPAR-alpha activation and mast cell down-regulation, the same pathway described in this site’s articles on PEA and neuroinflammation. In the eye specifically, the trabecular meshwork that drains aqueous humor is sensitive to inflammatory signaling, and endocannabinoid-related compounds have documented effects on outflow. The neuroprotection argument is separate: if retinal ganglion cells are dying partly through inflammatory and excitotoxic mechanisms, a compound that calms glial and mast cell activation could in principle slow that independent of pressure.
That is the theory. The trials are what test it.
The 2011 Crossover Trial: The Strongest Single Piece of Evidence
The most methodologically clean study is a prospective, randomized, double-blind, crossover trial published in Investigative Ophthalmology and Visual Science. Forty-two patients with primary open-angle glaucoma or ocular hypertension, all already treated with timolol 0.5% and all with IOP still sitting in the 19 to 24 mmHg range, received either oral PEA 300 mg twice daily or a matched placebo for two months, then crossed over after a two-month washout [1].
The result was clear. Starting from a mean baseline IOP of 21.6 mmHg, the PEA period produced a reduction of 3.2 mmHg at one month and 3.5 mmHg at two months, which works out to roughly a 16% drop. The placebo period, from a nearly identical baseline of 21.5 mmHg, produced 0.4 and 0.3 mmHg respectively. The difference between conditions was statistically significant at both timepoints. No adverse events, visual acuity changes, or vital sign changes were detected [1].
Two design features make this study worth taking seriously. The crossover structure means each patient acts as their own control, which removes a lot of between-person variation. And the fact that everybody stayed on timolol throughout means the effect measured is an additional pressure reduction on top of a working prescription drug, not PEA competing against nothing.
The Normal-Tension Glaucoma Study: Pressure Plus Visual Field
Normal-tension glaucoma is the harder problem. These patients have optic nerve damage progressing despite IOP that already sits in the statistically normal range, so the standard lever of pressure-lowering has less room to work.
A 2014 study in Journal of Medical Food enrolled 32 consecutive normal-tension glaucoma patients, randomized 1:1 to either ultramicronized PEA 300 mg twice daily for six months, or no treatment. In the PEA group, IOP fell from a baseline of 14.4 mmHg to 11.1 mmHg. More interestingly, visual field parameters improved significantly relative to baseline, with mean deviation moving from -7.65 dB to -4.55 dB and pattern standard deviation from 5.21 to 3.81 dB. Neither changed in the comparison group. A generalized linear model found the final IOP and visual field values were predicted by PEA treatment and not by demographic or clinical differences between groups [2].
The honest caveat: this was an open-label design with an untreated rather than placebo-treated control group. Visual field testing is a subjective test that improves with practice, and patients who know they are being treated may test differently. That is a real limitation and it is why the next study matters.
The 2020 Trial: An Objective Electrophysiological Signal
Pattern electroretinogram (PERG) measures the electrical response of retinal ganglion cells directly. It does not depend on the patient pressing a button when they see a light, which sidesteps the practice-effect problem entirely.
A 2020 study in Scientific Reports ran a randomized, single-blind, two-period crossover in 40 stable glaucoma patients on topical monotherapy, comparing their existing drops alone against those drops plus PEA 600 mg once daily. Patients were evaluated at baseline, four months, and eight months. In the PEA period, P50-wave amplitude was significantly higher (mean difference 0.56 microvolts, 95% CI 0.30 to 0.73), IOP was 1.6 mmHg lower, and quality-of-life scores were 6.7 points higher [3].
The authors described this as the first study to show a PERG effect for PEA in glaucoma. An improvement in retinal ganglion cell electrical function is the kind of outcome that would support the neuroprotection hypothesis rather than just the pressure-lowering one, though a single crossover study in 40 people is a starting point, not a conclusion.
What the Meta-Analysis Says About the Size of This Literature
A 2025 systematic review and meta-analysis in Natural Product Research searched PubMed, Embase, and Web of Science through August 2023 for studies on PEA and IOP in eye disorders. From 828 records retrieved, six studies covering 199 patients total met inclusion criteria for the systematic review, and only three could be pooled in the meta-analysis. The pooled conclusion was that PEA significantly reduces IOP, and the authors framed it as encouraging for clinical use as an adjuvant [4].
Read that number again: 199 patients across the entire published literature. For comparison, a single phase III trial of a new glaucoma drop routinely enrolls several hundred. The direction of the evidence is consistent, and consistency across independent groups is meaningful, but the total volume is small enough that a couple of well-run negative trials could change the picture substantially.
Two Adjacent Findings: Post-Laser Pressure Spikes and Ocular Surface Disease
Two smaller studies address situations glaucoma patients actually encounter rather than baseline pressure control.
The first looked at Nd:YAG laser iridotomy, a procedure done to prevent angle-closure glaucoma that commonly causes a short-term IOP spike afterward. Fifteen patients were pretreated with either PEA or placebo, two tablets daily for fifteen days before the procedure. Postoperative IOP rose significantly in the placebo-pretreated eyes but not in the PEA-pretreated ones, and the regression slopes differed significantly between conditions [5]. The sample is tiny, but the mechanism proposed, PEA blunting the post-procedure inflammatory response, is consistent with everything else known about the compound.
The second addresses a problem that limits long-term glaucoma management: chronic use of hypotensive eye drops inflames the ocular surface, and that inflammation is a major reason patients stop using their drops. A pilot trial gave 15 glaucoma patients topical PEA in addition to their antiglaucoma drugs while 15 received no additional treatment. By day 30, the PEA group showed improved Schirmer test scores, improved tear film breakup time, and reduced conjunctival hyperemia compared with baseline, with the hyperemia difference reaching significance against the control group by day 15 [6]. This site covers the broader topical PEA and dry eye literature in a separate article; the specific point here is the interaction with glaucoma medication, not dry eye in general.
What This Does and Does Not Mean in Practice
Every trial described above used PEA as an addition to existing treatment. Nobody randomized patients to PEA instead of their drops, and given that untreated glaucoma progresses to irreversible vision loss, nobody is likely to. A 3 mmHg reduction on top of a prescription is a meaningful number in a disease where every millimeter of mercury matters over decades, but it is not a replacement for the prescription.
The doses used clustered around 600 mg per day, delivered either as 300 mg twice daily or 600 mg once daily, which is the same range used across the general PEA pain literature and covered in this site’s dosage guide. The formulations were micronized or ultramicronized in the studies that specified, consistent with the bioavailability picture described in the micronized versus ultramicronized article. Trial durations ran from one to eight months.
The practical framing is this: PEA in glaucoma is an adjunct with a small but internally consistent evidence base, an unusually clean safety record across those trials, and no demonstrated ability to substitute for pressure-lowering medication. Anyone with glaucoma considering it should be raising it with their ophthalmologist, not deciding independently, because IOP needs to be measured to know whether anything is working.
Frequently Asked Questions
Does PEA lower eye pressure in people without glaucoma?
The trials enrolled people with glaucoma or ocular hypertension, meaning elevated pressure was the entry condition. There is no published evidence on what PEA does to normal IOP in healthy eyes, and no reason to think lowering already-normal pressure would be beneficial.
How long did it take for the pressure effect to appear?
In the 2011 crossover trial, most of the reduction was present by one month (3.2 mmHg) with only a small further drop by two months (3.5 mmHg) [1]. That is broadly in line with the general PEA onset timeline covered elsewhere on this site.
Is oral or topical PEA better for eye conditions?
They appear to do different jobs. The IOP-lowering trials all used oral PEA. The topical formulation was studied for ocular surface inflammation caused by glaucoma drops, which is a different problem [6]. There is no head-to-head comparison.
Can PEA replace glaucoma eye drops?
No, and no study has tested that. Every trial kept patients on their existing therapy. Stopping prescribed glaucoma treatment risks permanent vision loss.
Why is this research almost entirely Italian?
PEA has been developed and marketed as a medical food primarily in Italy, so Italian academic ophthalmology groups had access to standardized formulations early. It is a reason to want independent replication elsewhere, not a reason to dismiss the findings.
References
- Gagliano C, Ortisi E, Pulvirenti L, et al. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial. Invest Ophthalmol Vis Sci (2011). PMID 21705689
- Costagliola C, Romano MR, dell’Omo R, et al. Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up. J Med Food (2014). PMID 24827384
- Rossi GCM, Scudeller L, Lumini C, et al. Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram. Sci Rep (2020). PMID 32591562
- Crupi L, Capra AP, Paterniti I, et al. Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. Nat Prod Res (2025). PMID 38269580
- Pescosolido N, Librando A, Puzzono M, Nebbioso M. Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study. J Ocul Pharmacol Ther (2011). PMID 21830944
- Di Zazzo A, Roberti G, Mashaghi A, et al. Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications. J Ocul Pharmacol Ther (2017). PMID 29045169
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
